CNR1 and metabolic disease: The authors suggested that CB1 blockade alleviates diet-induced obesity and metabolic disorders by modulating macrophage inflammatory mediators, and this effect is linked to changes in the gut microbiome and its metabolites (Mehrpouya-Bahrami et al. 2017).